valsartan has been researched along with Lymphoma, Non-Hodgkin in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Hino, M; Nakamae, H; Nakamae, M; Nakane, T; Ohta, K; Terada, Y; Tsumura, K; Yamane, T | 1 |
1 trial(s) available for valsartan and Lymphoma, Non-Hodgkin
Article | Year |
---|---|
Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Atrial Natriuretic Factor; Biomarkers; Cyclophosphamide; Doxorubicin; Female; Hemodynamics; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Natriuretic Peptide, Brain; Neoplasm Staging; Prednisone; Tetrazoles; Valine; Valsartan; Vincristine | 2005 |